FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Predicting Chemo Benefit in Breast Cancer With EndoPredict Predicting Chemo Benefit in Breast Cancer With EndoPredict
Can a clinicomolecular score reliably predict absolute benefit of chemotherapy in women with HER2-negative, ER-positive breast cancer?JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

OHSU spinout raised $1.5M for cancer drug platform
An Oregon Health& Science University spinout raised $1.5 million, which will help advance its cancer drug candidate toward a clinical trial. PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni& Joan E. Kuni Foundation, based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities& Exchange Commission. PDX Pharmaceuticals’ first drug candidate is targeted for treatment of HER2-positive breast cancer, which accounts for… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 3, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

OHSU spinout raised $1.5M for cancer drug platform
An Oregon Health& Science University spinout raised $1.5 million, which will help advance its cancer drug candidate toward a clinical trial. PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni& Joan E. Kuni Foundation, based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities& Exchange Commission. PDX Pharmaceuticals’ first drug candidate is targeted for treatment of HER2-positive breast cancer, which accounts for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 3, 2019 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Phase III HLX02 Study Meets Primary End Point in Patients with HER2+ Breast Cancer
Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24. (Source: CancerNetwork)
Source: CancerNetwork - November 26, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
(European Society for Medical Oncology) The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer
A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'
(European School of Oncology) Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1 -- a drug that combines trastuzumab with an anti-cancer drug called DM1. The research is presented at the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) and published simultaneously in published in Clinical Breast Cancer journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2019 Category: Cancer & Oncology Source Type: news

Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

First HER2/4-1BB Bispecific Molecule Shows Clinical Activity in HER2+ Cancers
PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news

Trial Results Support Frontline Use of T-DM1 in HER2 ‐Positive Metastatic Breast Cancer
Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2 ‐positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

HER2/HER3 Antibody Therapeutic Shows Potential in NRG1-Fusion-Positive Solid Tumors
MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

What Is the Risk of Recurrence in HER2-Positive Breast Cancer?
Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis. (Source: CancerNetwork)
Source: CancerNetwork - October 24, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tucatinib Improves PFS, OS in HER2-Positive Metastatic Breast Cancer
Tucatinib showed improvements in survival in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 24, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Metastatic Breast Cancer Highlights From ESMO 2019 Metastatic Breast Cancer Highlights From ESMO 2019
Metastatic breast cancer highlights from ESMO 2019 confirm that CDK4/6 inhibition gives survival benefit in HR+/HER2- breast cancer and that immunotherapy is active in the neoadjuvant setting in TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. (Source: World Pharma News)
Source: World Pharma News - October 17, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

What Factors Can Predict Response to HER2-Directed Neoadjuvant Therapy?
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study. (Source: CancerNetwork)
Source: CancerNetwork - October 16, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer
Is neoadjuvant T-DM1 plus pertuzumab associated with better event-free survival than conventional neoadjuvant therapy for HER2+ breast cancer?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

ASCO/CAP Update of Breast Cancer HER2 FISH Testing Guidelines ASCO/CAP Update of Breast Cancer HER2 FISH Testing Guidelines
How have the recently updated ASCO/CAP HER2 FISH testing guidelines for breast cancer impacted positivity rates?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Dr. Emens Discusses Overall Survival in HER2+ Breast Cancer
Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study. (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Leisha A. Emens, MD, PhD Source Type: news

Can a PARP Inhibitor-Chemotherapy Combination Improve Advanced Breast Cancer Outcomes?
The addition of the PARP inhibitor veliparib to carboplatin  and paclitaxel offered significant improvement to patients with HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer
New data for overall survival now establish adding the CDK4/6 inhibitors abemaciclib and ribociclib to endocrine therapy for frontline use in HR+/HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Does Adjuvant Therapy Benefit Those with Small HER2-Positive Breast Cancers?
The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small. (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
Roche today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in peo ple with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - September 13, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
Roche today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in peo ple with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2019 Category: Pharmaceuticals Source Type: news

UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news

Pyrotinib Combo Moves Forward in HER2-Positive Metastatic Breast Cancer
A new combo may benefit patients with  HER-2 positive metastatic breast cancer, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - September 4, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Medical News Today: What to know about HER2-negative breast cancer
There are two main types of HER2-negative breast cancer: hormone receptor-positive and triple-negative. Many treatments exist, and prognosis varies. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 20, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?
A new analysis looked at how dose interruptions or reductions of  ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

HER2 reduces the STING
The receptor tyrosine kinase HER2 inhibits STING activation and limits the immune response to DNA virus infection and cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 5, 2019 Category: Science Authors: Williams, E. R. Tags: STKE Editors ' Choice Source Type: news

Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival MONARCH 2 was a Phase 3 study including both pre/peri- and postmenopausal women whose cancer progresse... Biopharmaceuticals, Oncology Eli Lilly, Verzenio, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2019 Category: Pharmaceuticals Source Type: news

MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer
The polycomb group gene MEL-18 may prevent trastuzumab resistance making it a potential novel biomarker for HER2+ breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HER2 Heterogeneity Impacts Response Rates in HER2-Positive Breast Cancer
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - July 19, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nanomedicine Approach Could Offer New Way to Target HER2+ Breast Cancer
Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Novel Conjugate Shows Promise in HER2-Expressing Cancers
Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Imprinted spheres fight breast cancer
(Wiley) A particularly aggressive, metastasizing form of cancer, HER2-positive breast cancer, may be treated with nanoscopic particles " imprinted " with specific binding sites for the receptor molecule HER2. As reported by Chinese researchers in the journal Angewandte Chemie, the selective binding of the nanoparticles to HER2 significantly inhibits multiplication of the tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2019 Category: Cancer & Oncology Source Type: news

Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update
This study examined how the revised 2018 ASCO/CAP HER2 scoring criteria update impacted rates of HER2 equivocal and positive breast cancer diagnoses in a single institution.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

De-Escalation of Trastuzumab Remains Controversial in HER2+ Breast Cancer
After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Two-in-one drug combining Herceptin with chemotherapy keeps women's breast cancers at bay
(Institute of Cancer Research) Guiding chemotherapy to a tumor by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.The two-in-one treatment kept breast cancer at bay in women with a type of the disease called HER2-positive breast cancer who had stopped responding to existing drugs. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 27, 2019 Category: International Medicine & Public Health Source Type: news

De-escalating breast cancer therapy; can some patients be spared chemotherapy?
(Baylor College of Medicine) Researchers develop molecular testing to distinguish patients who may need less from those who may need more therapy for HER2 positive breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2019 Category: International Medicine & Public Health Source Type: news

Drug Combo Slows Progression in Advanced Breast Cancer
Results seen for alpelisib plus fulvestrant in PIK3CA - mutated, HR + , HER2 − advanced breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 24, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Drug Combo Slows Progression in Advanced Breast Cancer
MONDAY, June 24, 2019 -- Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2019 Category: Pharmaceuticals Source Type: news

Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer
The new approval is for patients with germline BRCA-mutated, HER2 negative locally advanced or metastatic breast cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Early Breast Cancer Highlights From ASCO 2019 Early Breast Cancer Highlights From ASCO 2019
Dr Harold Burstein highlights ASCO oral presentations on early breast cancer, featuring neoadjuvant therapy in HER2-positive disease and updated data from the TAILORx study in HR-positive disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzumab)
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (Source: World Pharma News)
Source: World Pharma News - June 17, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news